Navigation Links
Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Date:10/2/2008

t of cancer through its affinity for a novel target, lactadherin. Lactadherin is an extracellular matrix protein that is released by numerous types of tumor cells, including most breast cancers, ovarian cancers and prostate cancer. Lactadherin has a critical role in promoting the growth of new blood vessels to support tumor growth through the activation of VEGF-mediated angiogenesis. The target lactadherin and Angiolix are supported and protected by granted patents.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has ... Market by Product, Application, Technology, End User - Global ... The infectious disease diagnostics market is expected ... million by 2019 from $12,422.8 million in 2014. Increase ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) ... by Allergen Source, Product & by End User - Global ... The global allergy diagnostics market is valued at $1,228.58 ... CAGR of 12.67%, to reach $2,230.72 million by 2019. Allergy ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... May 2, 2011 Henry Schein, Inc., (NASDAQ: ... services to office-based practitioners, announced today that Stanley ... and Steven Paladino, the Company,s Executive Vice President and Chief ... Health Care Conference on May 4, 2011. The conference is ...
... Spain, May 2, 2011 Grifols, S.A. ("Grifols") and ... have signed a "Consent Agreement" with the Staff of ... Commission (FTC) by means of which the conditions for ... Consent Agreement is subject to approval of the FTC ...
Cached Medicine Technology:Henry Schein to Present at Deutsche Bank 36th Annual Health Care Conference 2Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 2Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 3Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 4Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement With FTC Staff 5
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... The Health Ethics Trust, a Division of the Council ... Compliance program an unconditional three-year certification effective October 5, ... month intensive review of the NHS program which included ... of highly respected compliance experts from around the country ...
... Hamilton, ON (Oct. 14, 2009) When people travel, bacteria ... billion people cross international borders each year, many more billions ... However, the trend is contributing to substantial domestic and international ... more recently with the H1N1 flu virus. In a ...
... prevent fever at shot time could be counterproductive, researchers say ... vaccination is a normal and essential part of building ... in the U.S. as Tylenol -- after a shot could ... vaccines, transient fever means that a child,s immune system is ...
... ... Suzanne Somers’ new book. , ... Potomac, MD (PRWEB) October 15, 2009 — Julian Whitaker, MD, has the distinct honor ... Curing Cancer and How to Prevent Getting It In the First Place. The book highlights ...
... Inc., today announced that Grant Asay has been promoted ... specialty acute care hospital system. As executive vice president ... quality of care and governance of all LifeCare hospitals. ... with more than 22 years experience. He joined LifeCare ...
... HARBIN, China, Oct. 15 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... today reported the,operating results for the first quarter of ... revenue grew 50% to $6.43 million from $4.28 million ... first quarter grew 68% to $2.43,million and fully diluted ...
Cached Medicine News:Health News:Paradigm shift needed to combat drug resistance 2Health News:Acetaminophen May Weaken Effectiveness of Kids' Vaccines 2Health News:Dr. Julian Whitaker Pens Forward for Suzanne Somers' New Cancer Book 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 2Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 3Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 4Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 5Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 6Health News:SOKO Fitness & Spa Group Reports Quarterly Earnings Growth Over Fiscal 2009 First Quarter 7
ISI Alumi-Hand is the safe, sterile, ready-to-use ,surgical hand immobilizer....
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
ISI Ultra-Light Specialty Table offers the ultimate accessibility for surgeons, technicians and equipment during upper extremity surgeries....
MagPrep® Streptavidin Beads are encapsulated super-paramagnetic polystyrol particles coated with streptavidin. The beads have a diameter of 1 m and are provided as a stabilized aqueous suspensio...
Medicine Products: